Table 3.
Summary of glycosphingolipids characterized in the subfractions isolated from human stomachs
| Fraction | Amount | Migration | Glycosphingolipid | Abbreviation |
|---|---|---|---|---|
| mg | ||||
| P-I | 0.4 | Mono | Galβ1Cer | GalCer |
| Glcβ1Cer | GlcCer | |||
| P-II | 1.2 | Di + tri | Galβ4Glcβ1Cera | LacCer |
| Galα4Galβ1Cer | Galabia | |||
| Galα4Galβ4Glcβ1Cer | Gb3 | |||
| P-III | 1.3 | Tri + tetra | Galα4Galβ4Glcβ1Cer | Gb3 |
| GlcNAcβ3Galβ4Glcβ1Cer | Lc3 | |||
| GalNAcβ3Galα4Galβ4Glcβ1Cer | Gb4 | |||
| Galβ3GlcNAcβ3Galβ4Glcβ1Cer | Lc4 | |||
| Galβ4GlcNAcβ3Galβ4Glcβ1Cer | nLc4 | |||
| Galβ4 (Fucα3)GlcNAcβ3Galβ4Glcβ1Cer | Lex-5 | |||
| P-IV | 0.7 | ≥Tetra | GalNAcβ3Galα4Galβ4Glcβ1Cer | Gb4 |
| Galβ4GlcNAcβ3Galβ4Glcβ1Cer | nLc4 | |||
| GalNAcβ3Galβ4GlcNAcβ3Galβ4Glcβ1Cer | x2 | |||
| Fucα2Galβ3GlcNAcβ3Galβ4Glcβ1Cer | H5-1 | |||
| Fucα2Galβ4GlcNAcβ3Galβ4Glcβ1Cer | H5-2 | |||
| Galβ3 (Fucα4)GlcNAcβ3Galβ4Glcβ1Cer | Lea-5 | |||
| Galβ4 (Fucα3)GlcNAcβ3Galβ4Glcβ1Cer | Lex-5 | |||
| Galβ4GlcNAcβ3Galβ4GlcNAcβ3Galβ4Glcβ1Cer | nLc6 | |||
| Fucα2Galβ3 (Fucα4)GlcNAcβ3Galβ4Glcβ1Cer | Leb-6 | |||
| Fucα2Galβ4 (Fucα3)GlcNAcβ3Galβ4Glcβ1Cer | Ley-6 | |||
| GalNAcα3 (Fucα2)Galβ4GlcNAcβ3Galβ4Glcβ1Cer | A6-2 | |||
| Fucα2Galβ4GlcNAcβ3Galβ4GlcNAcβ3Galβ4Glcβ1Cer | H7-2 | |||
| GalNAcα3 (Fucα2)Galβ3 (Fucα4)GlcNAcβ3Galβ4Glcβ1Cer | A7-1 | |||
| GalNAcα3 (Fucα2)Galβ4 (Fucα3)GlcNAcβ3Galβ4Glcβ1Cer | A7-2 | |||
| GalNAcα3 (Fucα2)Galβ4GlcNAcβ3Galβ4GlcNAcβ3Galβ4Glcβ1Cer | A8-2 | |||
| p-I | 1.3 | Mono | Galβ1Cer | GalCer |
| Glcβ1Cer | GlcCer | |||
| p-II | 0.7 | Di | Galβ4Glcβ1Cer | LacCer |
| p-III | 0.3 | Tetra | GlcNAcβ3Galβ4Glcβ1Cer | Lc3 |
| Galβ3GlcNAcβ3Galβ4Glcβ1Cer | Lc4 | |||
| Galβ4GlcNAcβ3Galβ4Glcβ1Cer | nLc4 | |||
| Fucα2Galβ4GlcNAcβ3Galβ4Glcβ1Cer | H5-2 | |||
| Galβ4 (Fucα3)GlcNAcβ3Galβ4Glcβ1Cer | Lex-5 | |||
| GalNAcα3 (Fucα2)Galβ4GlcNAcβ3Galβ4Glcβ1Cer | A6-2 | |||
| p-IVb | 1.2 | ≥Tetra | Galβ4GlcNAcβ3Galβ4Glcβ1Cer | nLc4 |
| GalNAcβ3Galβ4GlcNAcβ3Galβ4Glcβ1Cer | x2 | |||
| Fucα2Galβ4GlcNAcβ3Galβ4Glcβ1Cer | H5–2 | |||
| Galβ3 (Fucα4)GlcNAcβ3Galβ4Glcβ1Cer | Lea-5 | |||
| Galβ4 (Fucα3)GlcNAcβ3Galβ4Glcβ1Cer | Lex-5 | |||
| Galβ4GlcNAcβ3Galβ4GlcNAcβ3Galβ4Glcβ1Cer | nLc6 | |||
| Fucα2Galβ3 (Fucα4)GlcNAcβ3Galβ4Glcβ1Cer | Leb-6 | |||
| Fucα2Galβ4 (Fucα3)GlcNAcβ3Galβ4Glcβ1Cer | Ley-6 | |||
| GalNAcα3 (Fucα2)Galβ4GlcNAcβ3Galβ4Glcβ1Cer | A6-2 | |||
| GalNAcα3 (Fucα2)Galβ3 (Fucα4)GlcNAcβ3Galβ4Glcβ1Cer | A7-1 | |||
| GalNAcα3 (Fucα2)Galβ4 (Fucα3)GlcNAcβ3Galβ4Glcβ1Cer | A7-2 | |||
| Galβ3/4GlcNAcβ3Galβ4 (Fucα3)GlcNAcβ3Galβ4Glcβ1Cer | Galβ3/4GlcNAcβ3- Lex-5 | |||
| Galβ4 (Fucα3)GlcNAcβ3Galβ4GlcNAcβ3Galβ4Glcβ1Cer | Lex-7 | |||
| Fucα2Galβ4GlcNAcβ3Galβ4GlcNAcβ3Galβ4Glcβ1Cer | H7-2 | |||
| Galβ4GlcNAcβ3Galβ4GlcNAcβ3Galβ4GlcNAcβ3Galβ4Glcβ1Cer | nLc8 | |||
| GalNAcα3 (Fucα2)Galβ4GlcNAcβ3Galβ4GlcNAcβ3Galβ4Glcβ1Cer | A8–2 | |||
| Fucα2Galβ3/4GlcNAcβ3Galβ4 (Fucα3)GlcNAcβ3Galβ4Glcβ1Cer | Fucα2Galβ3/4-GlcNAcβ3-Lex-5 | |||
| Fucα2Galβ4 (Fucα3)GlcNAcβ3Galβ4GlcNAcβ3Galβ4Glclcβ1Cer | Ley-8 | |||
| Fucα2Galβ4GlcNAcβ3Galβ4GlcNAcβ3Galβ4GlcNAcβ3Galβ4Glcβ1Cer | H9–2 | |||
| Fucα2Galβ4 (Fucα3)GlcNAcβ3Galβ4 (Fucα3)GlcNAcβ3Galβ4Glclcβ1Cer | Ley-9 |
a The compounds in boldface type have been characterized as H. pylori binding in previous studies (summarized in Table 1).
b The glycosphingolipids listed under fraction p-IV were characterized by LC-ESI/MS and MS2 of fractions p-IVa–f.